Rising to the formidable challenge presented by the COVID-19 pandemic, the biopharmaceutical industry is embracing a spirit of collaboration to advance the development of vaccines and therapeutic interventions that can prevent disease or speed recovery. This has resulted in a steady stream of new alliances that bring together complementary assets, resources and expertise. Existing partners are also broadening the scope of ongoing collaborations to include COVID-19 R&D.